CEFIDEROCOL SULFATE TOSYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for cefiderocol sulfate tosylate and what is the scope of freedom to operate?
Cefiderocol sulfate tosylate
is the generic ingredient in one branded drug marketed by Shionogi and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for CEFIDEROCOL SULFATE TOSYLATE
| International Patents: | 86 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CEFIDEROCOL SULFATE TOSYLATE |
| What excipients (inactive ingredients) are in CEFIDEROCOL SULFATE TOSYLATE? | CEFIDEROCOL SULFATE TOSYLATE excipients list |
| DailyMed Link: | CEFIDEROCOL SULFATE TOSYLATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CEFIDEROCOL SULFATE TOSYLATE
Generic Entry Date for CEFIDEROCOL SULFATE TOSYLATE*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for CEFIDEROCOL SULFATE TOSYLATE
| Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CEFIDEROCOL SULFATE TOSYLATE
US Patents and Regulatory Information for CEFIDEROCOL SULFATE TOSYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shionogi | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shionogi | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shionogi | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CEFIDEROCOL SULFATE TOSYLATE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015312828 | ⤷ Start Trial | |
| Brazil | 112017004166 | ⤷ Start Trial | |
| Canada | 2959295 | ⤷ Start Trial | |
| China | 106795176 | ⤷ Start Trial | |
| Cyprus | 1124838 | ⤷ Start Trial | |
| Denmark | 3190115 | ⤷ Start Trial | |
| Eurasian Patent Organization | 035845 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CEFIDEROCOL SULFATE TOSYLATE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2960244 | 2020/044 | Ireland | ⤷ Start Trial | PRODUCT NAME: CEFIDEROCOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT REGISTRATION NO/DATE: EU/1/20/1434 20200424; FIRST REGISTRATION NO/DATE: EU/1/20/1434 20200424 |
| 2960244 | 43/2020 | Austria | ⤷ Start Trial | PRODUCT NAME: CEFIDEROCOL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS; REGISTRATION NO/DATE: EU/1/20/1434 (MITTEILUNG) 20200424 |
| 2960244 | 782 | Finland | ⤷ Start Trial | |
| 2960244 | 2020035 | Norway | ⤷ Start Trial | PRODUCT NAME: CEFIDEROKOL, EVENTUELT PA FORMEN AV ET FARMASOEYTISK AKSEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200508 |
| 2960244 | CA 2020 00049 | Denmark | ⤷ Start Trial | PRODUCT NAME: CEFIDEROCOL, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200424 |
| 2960244 | PA2020530 | Lithuania | ⤷ Start Trial | PRODUCT NAME: CEFIDEROKOLAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1434 20200423 |
| 2960244 | 2090041-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: CEFIDEROKOL; REG. NO/DATE: EU/1/20/1434 20200424 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch